Through its Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership, NIH has launched a suite of adaptive master protocol-driven clinal trials that have tested prioritized therapeutic candidates, including immune modulators, monoclonal antibodies, antithrombotics, and other therapies. These trials have generated biospecimens that could be critical research resources for further studies elucidating the pathobiology of COVID-19 and potentially identifying therapeutic targets. We would like to acknowledge the study participants who generously volunteered to participate in these research endeavors. The invaluable contributions of these volunteers are what makes this work possible.

While biospecimens are currently stored by each ACTIV study biorepository, this central web-based virtual biorepository portal provides a readily searchable systematic inventory of the samples and associated meta-data as well as the ability to apply for access to these biospecimens.

To request access to the virtual biorepository, please email activ-biorep@rti.org.